Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
Yale University
100 participants
Nov 7, 2023
INTERVENTIONAL
Conditions
Summary
The primary objective of this multimodal positron emission tomography (PET) study is to use PET brain imaging to measure both MOR (Mu-Opioid receptors) and KOR (kappa-opioid receptors) in participants with alcohol use disorder (AUD) and to quantify the relationships between MOR and KOR, separately and jointly, to key clinical outcomes (e.g., craving, mood, withdrawal, time to lapse) during a quit attempt.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will begin inpatient or outpatient detoxification prior to completing imaging
90 PET Imaging Scan using \[11C\]LY2795050 (AKA \[11C\]PKAB)
90 Pet Imaging Scan using \[11C\]-Carfentanil
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05957159